Search PubMed⌕ Search

Biomedical subjects

I V Maev

Publications and source records attributed to I V Maev.

At least 37 records · Page 2Linked to original sources
PubMed2003

[New regulatory peptides in rat stomach secretion (amylin, PGP, semax)].

We showed antisecretory effects of peptides of PGP, semax and a new pancreatic hormone, amylin, on the model of continuous stomach perfusion with the registration of pH, PCO2 as well as the determination of the amount of pepsinogen in the stomach perfusate. The intraperitoneal introduction of these peptides in the doses that proved to have an apparent anti-ulcer effect caused a decrease of both basal production of hydrochloric acid in the stomach and production caused by the irritation of the vagus nerve. Semax and amylin also decreased basal and stimulated secretion of pepsinogen. Amylin and PGP did not have any effect on basal bicarbonate secretion of the stomach, and semax caused its short-time increase 35 minutes after the introduction. We made a conclusion that the decrease of aggressive factors in gastric juices can be a mechanism of the anti-ulcer action of all three peptides under study.

Adrenocorticotropic Hormone↗
PubMed2003

[Microcirculatory disorders in chronic erosions of the stomach].

Microcirculatory disturbances in chronic gastric erosions (CGE) were evaluated in 95 chronic gastric (CGE) patients using Doppler laser flowmetry to examine terminal blood flow of the gastric mucosa. Microcirculatory impairment in the fundal area was found in 93.7% patients with CGE, in the antral one in all the examinees. Patients with multiple and recurrent erosions and erosions associated with Helicobacter pylori had most pronounced microcirculatory disorders, especially in the antral stomach. When chronic erosions were treated with triad therapy on the basis of De-nol, the percentage of eradication exceeded 80%. The addition to therapy of the immunomodulator galavit promotes more effective and adequate restoration of blood flow in CGE patients.

Adjuvants, Immunologic↗
PubMed2003

[Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease].

The purpose of this study is a comparative assessment of the clinical efficiency of Omeprazole and Esomeprazole in patients suffering from bronchial asthma (BA) with associated gastroesophageal reflux disease (GERD). 101 patients with BA and associated GERD being under study were divided into three groups depending on the way of application of the anti-reflux therapy. Patients from the I group were administered Omeprazole--20 mg per day, patients from the II group received Omeprazole--mg per day, and patients from the III group were administered Esomeprazole--40 mg per day, the treatment courses of each group amounting to eight weeks. The clinical efficiency indices of pulmonary (CEIP) and esophageal (CEIE) symptoms were calculated when the results of the study were summed. The decrease of CEIP and CEIE against the background of the anti-reflux therapy (for example, the CEIP of patients from the III group decreased from 14.9 +/- 1.5 (before the treatment) to 2.9 +/- 0.6 points following eight weeks of treatment (p < 0.001), and the CEIE decreased from 9.0 +/- 1.2 (before the treatment) to 1.7 +/- 0.3 points following eight weeks of treatment (p < 0.001)) has demonstrated the reliable improvement of the clinical course of BA with associated GERD. We failed to discover any essential differences between the impact of Omeprazole in the dose equal to 40 mg per day and the impact of Esomeprazole in the same dose on the CEIP. Thus, the CEIP amounted to 10.1 +/- 1.2 points in the II group and 8.5 +/- 1.4 points in the III group (p > 0.05) after the fourth week of treatment. At the same time, we have discovered a reliable advantage of Esomeprazole as compared with Omeprazole for the improvement of the CEIE. The therapy of BA with associated GERD with Omeprazole in the dose equal to 40 mg per day or Esomeprazole in the dose equal to 40 mg per day contributes to the reliable improvement of both pulmonary and esophageal symptoms, and application of Esomeprazole results in a faster reduction of bronchial obstruction and gastroesophageal reflux.

Adult↗
PubMed2003

[Clinical assessment of the efficacy of early enteral nutrition with the help of "peptamen" nutriment in patients who underwent gastrectomy due to stomach cancer].

The protein-energetic insufficiency in cancer patients aggravates the course of the disease and leads to various complications in the post-operative period including lethal outcomes. The purpose of the study is to assess the efficiency of the use of the Peptamen compound in the early post-operative period in patients with moderate and serious degrees of protein-energetic insufficiency, who underwent gastrectomy due to stomach cancer. Two groups of patients were studied differing by the method of nutritional support. The use of the Peptamen compound in the early post-operative period leads to the improvement of the absorption of nutrients, increase in the functional activity of the intestine and immunomodulation, and as a result of this, to the reduction of post-operative complications and fast restoration of homeostasis.

Adult↗
PubMed2003

[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].

Gastroesophageal reflux disease (GERD) is a wide spread disease characterized by distinct clinical polymorphism manifesting with various symptoms and/or inflammatory changes of a distal portion of the esophagus. Current first-line therapy in GERD consists in administration of proton pump inhibitors (PPI) which promote faster relief of the symptoms and healing of erosive-ulcerous lesions of esophageal mucosa in GERD patients. Clinical efficacy of standard and novel PPI is compared. Wide use of PPI and their long-term courses require further study of PPI side effects which now lack attention from the clinical researchers.

2-Pyridinylmethylsulfinylbenzimidazoles↗
PubMed2003

[Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].

The research was aimed at evaluating the efficiency of the inhibitor of the Rabeprazole (Pariet) proton pump in the therapy of the gastroesophageal reflux disease (GERD) with extra esophagus manifestations, and the presence of pains in the chest not caused by cardiac diseases. 37 patients suffering from GERD underwent monotherapy with inhibitors of the proton pump: 17 patients were taking Omeprazole 40 mg a day, and 20 patients--Rabeprazole 20 mg a day. The treatment with Rabeprazole supplied authentic data concerning faster pain reduction in the heart area and heartburn starting from the first day of treatment. According to the daily pH monitoring, administration of Pariet is accompanied by a reliably much more manifested reduction of the total time with pH less than 4 in the esophagus as compared to Omeprazole. The data received demonstrate the advantages of using Pariet in the treatment of GERD with atypical symptoms.

2-Pyridinylmethylsulfinylbenzimidazoles↗
PubMed2003

[Results of an open multicenter study of the efficiency of one-week anti-helicobacter therapy using omeprazole, clarithromycin, and amoxicillin in patients with duodenal peptic ulcer].

AIM: To study the efficiency of one-week antihelicobacter therapy using omeprazole, clarithromycin, and amoxycillin in patients with duodenal peptic ulcer during its recurrence. MATERIALS AND METHODS: 105 patients with recurrent peptic ulcer and a not less than 0.5-cm ulcer in the duodenal bulb was given triple therapy: omeprazole, 20 mg twice daily, amoxycillin, 1000 mg twice daily, and clarithromycin, 500 mg twice daily for 7 days. Then the patients were allowed to take antacids if they were required to abolish the symptoms of recurrent peptic ulcer. H. pylori was detected in the mucosal biopsy specimens taken from the anthral part and body of the stomach at gastroduodenascopy, by using the rapid urease test and histology. Gastroduodenoscopy was performed before and 4-6 weeks after the triple therapy. RESULTS: The major symptoms of recurrent peptic ulcer were eliminated in 90% of the patients by the end of a course of therapy, i.e. on its day 7. By the control time, the rate of ulcer cicatrization was 99.05% (104/105). The coincidence of results of the two tests has indicated that H. pylori eradication was 81.9% (86/105) 4-6 weeks after termination of treatment. Adverse reactions during therapy were observed in 20% of the patients; however, treatment had to be discontinued only in 2.9% of the patients. CONCLUSION: One-week triple therapy using omeprazole, clarithromycin, and amoxycillin in highly effective in treating duodenal peptic ulcer during its recurrence.

Adolescent↗
PubMed2002

[The role of cytokines in pathogenesis of nonspecific ulcerative colitis].

Etiology of nonspecific ulcerous colitis (NSUC) as well as its pathogenetic mechanisms remain obscure. Cytokines are presently shown to play an essential role in development of inflammation. Cytokines are produced by the cells in the inflammatory infiltrate in NSUC, therefore, changes of their level in the blood and biopsies from colon mucosa is naturally determined. Current investigations register various changes in the levels of both proinflammatory and antiinflammatory cytokines. Further studies of unknown mechanisms of cytokines action may contribute to design of new methods of NSUC management.

Colitis, Ulcerative↗
PubMed2002

[Interferon status of patients with non-specific ulcerous colitis and its correction with interferon inducers].

AIM: To examine validity of using interferon inductors (amixin and cycloferon) in combined treatment of patients with non-specific ulcerous colitis (NUC). MATERIAL AND METHODS: 113 NUC patients received basic antiinflammatory therapy (glucocorticoids and preparations of 5-aminosalycylic acid). Patients of groups 1 and 2 received interferon inductors (amixin and cycloferon in tables), respectively. Patients of groups 1a and 2a received placebo. All the patients were examined clinically with evaluation of interferon status and cellular immunity before and after the treatment. Colon mucosa biopsies obtained endoscopically were studied histologically. RESULTS: Alpha- and gamma-interferon production by leukocytes was substantially suppressed in all the examinees against normal levels of serum and spontaneous interferon. The interferon inductors stimulated relief of clinical symptoms and eliminated endoscopic signs of the disease. Amixin and cycloferon normalized interferon status in 36.3 and 33.3% of the treated patients, respectively. No response was registered in 9.1 and 8.4%, respectively. Improvement was seen in 54.6 and 58.3%, respectively. CONCLUSION: Cycloferon and amixin, interferon inductors, are effective in the treatment of NUC.

Acridines↗
PubMed2002

[Chronotherapy approaches in the treatment of gastroduodenal ulcer].

Each patient with ulcer has his/her own 24-h biorhythm of acid production, features of food alkalization, duration of duodenogastric and gastroesophageal reflux. Pharmacological test conducted in prolonged 24-h pH-metry helps to select the most effective antisecretory drug, while analysis of 24-h biorhythm of acid production--optimal time for drug intake and number of its daily doses.

Anti-Ulcer Agents↗
PubMed2002

[The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].

Combined therapy with gepa-merz (L-ornitine-L-aspartate) and lactulose (a synthetic disaccharide) was given to 40 patients with hepatic encephalopathy and toxic hepatic cirrhosis in decompensation. Combination of gepa-merz with lactulose was effective in the above patients. Moreover, it is an optimal one as it has a double impact on ammonia toxicity which is a basic neurotoxin in pathogenesis of hepatic encephalopathy.

Adult↗
PubMed2002

[Side effects of current anti-Helicobacter therapy].

The article deals with side effects of present-day antihelicobacter therapy including side effects of some drugs with antisecretory and antibacterial action and complications observed in using combined treatment of helicobacteriosis (triple and quadrotherapy).

Anti-Ulcer Agents↗
PubMed2002

[Clinico-functional evaluation of the efficacy of treating gastroesophageal reflux disease combined with bronchial asthma with omeprazole].

AIM: To investigate the prevalence of gastroesophageal reflux disease (GERD) among patients with bronchial asthma (BA) and to determine the effects of omeprazole therapy on the outcome of asthma in patients with GERD. MATERIAL AND METHODS: 117 BA patients were examined. Those who had a concomitant GERD were divided into two groups to receive outpatiently omeprazole 40 mg/day or placebo for 8 weeks. Spirometry was performed before and after the treatment. Clinical indices were calculated by daily summarizing of pulmonary (CIEI I) and gastric (CIEI II) symptoms improvement. RESULTS: The trial showed a significant correlation between CIEI I and CIEI II (r = 0.574, p < 0.001) during 8-week omeprazole therapy. The analysis of PEV and FEV1 dynamics showed a significant improvement (p < 0.05) of bronchial conduction in BA patients receiving omeprazole vs placebo. CONCLUSION: A significant correlation exists between the severity of gastroesophageal refluxes and bronchoobstructive syndrome in BA and GERD patients. Omeprazole treatment of such patients relieves BA and GERD symptoms.

Adult↗